<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666351</url>
  </required_header>
  <id_info>
    <org_study_id>HM_AMO_401</org_study_id>
    <nct_id>NCT03666351</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease</brief_title>
  <official_title>A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation&#xD;
      between the intensive care group and the usual care group for patients with hypertension&#xD;
      accompanied by aortic valve disease and evaluate an influence of blood pressure regulation on&#xD;
      improvement of left ventricular hypertrophy and its safety&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.Primary objectives&#xD;
&#xD;
      - To evaluate changes from baseline in LVM at V5 (24M)&#xD;
&#xD;
      2.Secondary objectives&#xD;
&#xD;
        1. To evaluate changes from baseline in LV global longitudinal strain at V5 (24M)&#xD;
&#xD;
        2. To evaluate changes from baseline in E/E' (E: early diastolic LV inflow velocity, E':&#xD;
           early diastolic mitral annulus velocity) at V5 (24M)&#xD;
&#xD;
        3. To evaluate changes from baseline in LV volumes, a stroke volume index and LV ejection&#xD;
           fraction at V5 (24M)&#xD;
&#xD;
        4. To evaluate a rate of disease progression&#xD;
&#xD;
             -  In case of Aortic stenosis (AS), to evaluate changes from baseline in Aortic Valve&#xD;
                Area (AVA), Vmax, Mean Pressure Gradient (PG) and Valvulo-arterial impedance (Zva)&#xD;
                at V5 (24M)&#xD;
&#xD;
             -  In case of Aortic regurgitation (AR), to evaluate changes from baseline in Vena&#xD;
                contracta at V5 (24M)&#xD;
&#xD;
        5. To evaluate changes from baseline in blood pressure at V2(6M), V3(12M), V4(18M) and&#xD;
           V5(24M)&#xD;
&#xD;
        6. To evaluate a cumulative incidence rate for each visit time point&#xD;
&#xD;
             -  Death, Cardiovascular(CV) death, Heart Failure(HF), Myocardial Infarction(MI),&#xD;
                Hospitalization, Aortic Valve Replacement(AVR)&#xD;
&#xD;
        7. To evaluate outcomes of adverse events, physical examination, vital signs (pulse) and&#xD;
           laboratory tests (hematological examination, blood biochemical examination, urine test&#xD;
           and pregnancy test)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, multicentre, randomized, open label, evaluator-blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate changes from baseline in Left Ventricular Mass at 24M</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate changes from baseline in Left Ventricular Mass at 24M</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Left Ventricular global longitudinal strain at 24M</measure>
    <time_frame>24 months</time_frame>
    <description>Changes from baseline in Left Ventricular global longitudinal strain at 24M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in E/E' (E: early diastolic LV inflow velocity, E': early diastolic mitral annulus velocity) at 24M</measure>
    <time_frame>24 months</time_frame>
    <description>Changes from baseline in E/E' (E: early diastolic LV inflow velocity, E': early diastolic mitral annulus velocity) at 24M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Left Ventricular volumes at 24M</measure>
    <time_frame>24 months</time_frame>
    <description>Changes from baseline in Left Ventricular volumes at 24M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease progression</measure>
    <time_frame>24 months</time_frame>
    <description>In case of Aortic Stenosis, to evaluate changes from baseline in Aortic Valve Area, tricuspid regurgitation velocity, Mean Pressure Gradient and Valvulo-arterial impedance at 24M&#xD;
In case of Aortic Regurgitation, to evaluate changes from baseline in Vena contracta at 24M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate changes from baseline in systolic blood pressure at 6M, 12M, 18M, 24M</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <description>To evaluate changes from baseline in systolic blood pressure at 6M, 12M, 18M, 24M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate for each visit time point</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <description>Cumulative incidence rate for each visit time point&#xD;
- Death, Cardiovascular death, Heart Failure, Myocardial Infarction, Hospitalization, Aortic Valve Replacement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in stroke volume index at 24M</measure>
    <time_frame>24 months</time_frame>
    <description>Changes from baseline in stroke volume index at 24M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Left Ventricular ejection fraction at 24M</measure>
    <time_frame>24 months</time_frame>
    <description>Changes from baseline in Left Ventricular ejection fraction at 24M</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence and frequency of adverse events</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <description>Occurrence and frequency of adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Aortic Regurgitation</condition>
  <condition>Hypertension</condition>
  <condition>LVM</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>The intensive care group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.&#xD;
In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -&gt; Losartan and Amlodipine 5/50 mg -&gt; Losartan and Amlodipine 5/100 mg -&gt; Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The usual care group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.&#xD;
In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -&gt; Losartan and Amlodipine 5/50 mg -&gt; Losartan and Amlodipine 5/100 mg -&gt; Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <description>Amlodipine 5 mg</description>
    <arm_group_label>The intensive care group</arm_group_label>
    <arm_group_label>The usual care group</arm_group_label>
    <other_name>Amodipin Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan Potassium 50 mg</description>
    <arm_group_label>The intensive care group</arm_group_label>
    <arm_group_label>The usual care group</arm_group_label>
    <other_name>Osartan Tab. 50 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan and Amlodipine</intervention_name>
    <description>Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg</description>
    <arm_group_label>The intensive care group</arm_group_label>
    <arm_group_label>The usual care group</arm_group_label>
    <other_name>Amosartan Tab. 5/50 mg, Amosartan Tab. 5/100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine/Losartan/Chlorthalidone</intervention_name>
    <description>Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg</description>
    <arm_group_label>The intensive care group</arm_group_label>
    <arm_group_label>The usual care group</arm_group_label>
    <other_name>Amosartan Plus Tab. 5/100/12.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>current treatment</intervention_name>
    <description>treatment is done by maintaining the current treatment</description>
    <arm_group_label>The usual care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged ≥ 19 years and &lt; 80 years&#xD;
&#xD;
          2. Diagnosis of mild-moderate AS or mild-moderate AR&#xD;
&#xD;
          3. Applicable to 2.0~3.9 m/s of aortic jet velocity for mild-moderate AS or to 0.2~0.6 cm&#xD;
             of Vena contracta for mild-moderate AR&#xD;
&#xD;
          4. Diagnosis of hypertension (SBP &gt; 130 mmHg if being treated or SBP &gt; 140 mmHg if being&#xD;
             untreated)&#xD;
&#xD;
          5. For females of childbearing potential; negative pregnancy test results during the&#xD;
             screening period and prior to administration of the investigational product, and&#xD;
             agreement on use of medically allowable contraceptive measures (condom, oral&#xD;
             contraceptive pills, injectable or implantable contraceptives, intrauterine devices,&#xD;
             birth control patches, etc.) during the study period&#xD;
&#xD;
          6. Voluntary written consent to taking part in the clinical study and willingness to&#xD;
             comply with requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of a cardiac valve replacement surgery (replacement surgery of mitral valve,&#xD;
             aortic valve or tricuspid valve)&#xD;
&#xD;
          2. Accompanied by severe mitral regurgitation&#xD;
&#xD;
          3. Admitted to needing a surgery by the current treatment guidelines&#xD;
&#xD;
          4. Accompanied by symptoms such as angina pectoris, exertional dyspnea, syncope, etc.&#xD;
&#xD;
          5. &lt; 50% of left ventricular ejection fraction&#xD;
&#xD;
          6. History of hypersensitivity reaction to active ingredients of the investigational&#xD;
             product (Amlodipine, Losartan and Chlorthalidone), dihydropyridine derivatives,&#xD;
             thiazide drugs and other sulfonamide derivatives or their compositions&#xD;
&#xD;
          7. Pregnant or breastfeeding&#xD;
&#xD;
          8. Symptomatic orthostatic hypotension&#xD;
&#xD;
          9. Severe liver failure or renal failure (&lt; 30 mL/min of creatinine clearance)&#xD;
&#xD;
         10. Hereditary angioedema or history of angioedema at treatment with ACE inhibitors or&#xD;
             angiotensin II receptor blockers&#xD;
&#xD;
         11. Primary hyperaldosteronism&#xD;
&#xD;
         12. Genetic problems such as galactose intolerance, Lapp Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
         13. Anuria&#xD;
&#xD;
         14. Refractory hypokalemia&#xD;
&#xD;
         15. Hyponatremia or hypercalcemia&#xD;
&#xD;
         16. Symptomatic hyperuricemia (history of gout or uric acid lithiasis)&#xD;
&#xD;
         17. Untreated Addison's disease&#xD;
&#xD;
         18. Appropriately uncontrolled diabetes&#xD;
&#xD;
         19. Congenital or incurable hypertension&#xD;
&#xD;
         20. Diagnosis of severe cerebrovascular disorders (stroke, cerebral infarction, cerebral&#xD;
             hemorrhage, etc.) within six months prior to the date of ICF obtainment&#xD;
&#xD;
         21. Wasting disease, autoimmune disease or connective tissue disease&#xD;
&#xD;
         22. Diagnosis of malignant tumor within five years prior to the date of ICF obtainment&#xD;
&#xD;
         23. Administration of another investigational product within four weeks prior to the date&#xD;
             of ICF obtainment&#xD;
&#xD;
         24. For a patient who is taking anticoagulants and thrombolytic agents; considered&#xD;
             difficult to keep a stable dosage/regimen by the investigator.&#xD;
&#xD;
         25. Considered unsuitable to be a subject by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Hyun Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>10 institutions including Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong-Hwan Jeon</last_name>
    <phone>+821040984928</phone>
    <email>jonghwan06@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>10 Institutions Including Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Aortic Regurgitation</keyword>
  <keyword>Hypertension</keyword>
  <keyword>LVM</keyword>
  <keyword>Left Ventricular Hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>De-identified individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

